These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 12821613)

  • 41. Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE?
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):359-67. PubMed ID: 15025845
    [TBL] [Abstract][Full Text] [Related]  

  • 42. More evidence on blocking the renin-angiotensin-aldosterone system in cardiovascular disease and the long-term treatment of hypertension: data from recent clinical trials (CHARM, EUROPA, ValHEFT, HOPE-TOO and SYST-EUR2).
    Lip GY; Beevers DG
    J Hum Hypertens; 2003 Nov; 17(11):747-50. PubMed ID: 14578913
    [No Abstract]   [Full Text] [Related]  

  • 43. The kidney in cardiovascular disease.
    Kasiske BL
    Ann Intern Med; 2001 Apr; 134(8):707-9. PubMed ID: 11304109
    [No Abstract]   [Full Text] [Related]  

  • 44. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?
    Böhm M
    Am J Cardiol; 2007 Aug; 100(3A):38J-44J. PubMed ID: 17666197
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of ramipril on the circadian periodicity of acute myocardial infarction.
    Dagenais GR; Pogue J; Teo KK; Lonn EM; Yusuf S;
    Am J Cardiol; 2006 Sep; 98(6):758-60. PubMed ID: 16950179
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ["Using chance, despite high NNT"].
    Zeiher A
    MMW Fortschr Med; 2003 Sep; 145(38):12. PubMed ID: 14603674
    [No Abstract]   [Full Text] [Related]  

  • 47. [New hope concerning the prognosis of atherosclerosis].
    Kupari M
    Duodecim; 2000; 116(21):2317-9. PubMed ID: 12053357
    [No Abstract]   [Full Text] [Related]  

  • 48. Should the results of the HOPE study affect nephrological practice? For the HOPE investigators.
    Mann JF
    Nephrol Dial Transplant; 2000 Apr; 15(4):453-4. PubMed ID: 10727536
    [No Abstract]   [Full Text] [Related]  

  • 49. Safety and tolerability of ramipril 10 mg in patients at high risk of cardiovascular events: an observational study.
    Hathial M
    J Indian Med Assoc; 2008 Jul; 106(7):468-70, 480. PubMed ID: 18975506
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ramipril and risk of diabetes.
    Potyk DK
    JAMA; 2002 Jan; 287(2):186; author reply 186-7. PubMed ID: 11779250
    [No Abstract]   [Full Text] [Related]  

  • 51. The HOPE study and diabetes. Heart Outcomes Prevention Evaluation.
    Fegan G; Ward D; Clarke L; MacLeod K; Hattersley A
    Lancet; 2000 Apr; 355(9210):1182-3; author reply 1183-4. PubMed ID: 10791400
    [No Abstract]   [Full Text] [Related]  

  • 52. Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study)*.
    Schrader J; Lüders S; Kulschewski A; Hammersen F; Züchner C; Venneklaas U; Schrandt G; Schnieders M; Rangoonwala B; Berger J; Dominiak P; Zidek W;
    J Hypertens; 2006 Mar; 24(3):541-8. PubMed ID: 16467658
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril.
    Ferrari R
    Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):15-29. PubMed ID: 15723572
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HOPE in PROGRESS--a tale of two trials: blood pressure reduction or drug mechanism?
    Sander GE; Giles TD
    Am J Geriatr Cardiol; 2002; 11(5):332-3. PubMed ID: 12214175
    [No Abstract]   [Full Text] [Related]  

  • 55. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of ramipril on the incidence of diabetes.
    Potter BJ; LeLorier J
    N Engl J Med; 2007 Feb; 356(5):522-3; author reply 523-4. PubMed ID: 17274113
    [No Abstract]   [Full Text] [Related]  

  • 57. Effect of ramipril on the incidence of diabetes.
    Epstein BJ; Cooper-DeHoff RM
    N Engl J Med; 2007 Feb; 356(5):523; author reply 523-4. PubMed ID: 17269176
    [No Abstract]   [Full Text] [Related]  

  • 58. Ramipril and risk of diabetes.
    Shlossberg AH
    JAMA; 2002 Jan; 287(2):186-7. PubMed ID: 11779251
    [No Abstract]   [Full Text] [Related]  

  • 59. Update to the Consensus Document on Clinical Use of the Polypill: New Dose Containing Atorvastatin 40 mg.
    González-Juanatey JR
    Rev Esp Cardiol (Engl Ed); 2018 Jul; 71(7):595-596. PubMed ID: 29752030
    [No Abstract]   [Full Text] [Related]  

  • 60. From the Food and Drug Administration.
    Henney JE
    JAMA; 2000 Dec; 284(21):2711. PubMed ID: 11105160
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.